摘要
目的探讨聚乙二醇干扰素α2a(派罗欣)联合利巴韦林治疗慢性丙肝的临床疗效。方法选取2014年3月-2015年2月间我院收治的88例慢性丙肝患者,按照随机数字表法分为实验组与对照组,每组各44例。对照组患者予以常规疗法,实验组患者予以聚乙二醇干扰素α2a联合利巴韦林治疗,比较两组患者的治疗总有效率及不良反应。结果实验组与对照组患者的治疗总有效率分别为97.73%、84.09%,组间比较差异显著(P<0.05);实验组患者的不良反应发生率比对照组更低,差异有统计学意义(P<0.05);两组患者的复发率比较差异无统计学意义(P>0.05)。结论应用聚乙二醇干扰素α2a联合利巴韦林治疗慢性丙肝效果理想,且不良反应少,具有较高的临床推广价值。
Objective To explore the clinical efficacy of combination therapy of Pegasys with ribavirin for chronic hepatitis C. Methods From March 2014 to February 2015, 88 cases of chronic hepatitis C admitted in our hospital were divided into the experimental group and the control group according to random number table method, 44 cases in each group. The patients in the control group were given conventional therapy, while the patients in the experimental group were treated with Pegasys and ribavirin. The total effective rate and adverse reactions were compared between the two groups. Results The total effective rate of the experimental group and the control group were 97.73% and 84.09% respectively, and there was significant difference between the two groups （P〈0.05）. The incidence of adverse reactions in the experimental group was lower than that in the control group, and the difference was statistically significant （P〈0.05）. There was no significant difference in recurrence rate between the two groups （P〉0.05）. Conclusion The application of Pegasys and ribavirin in the treatment of chronic hepatitis C is ideal, with fewer adverse reactions, and has higher clinical value.
出处
《临床检验杂志（电子版）》
2016年第2期69-71,共3页
Clinical Laboratory Journal(Electronic Edition)
